These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 33337957

  • 1. Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.
    Awinda PO, Watanabe M, Bishaw Y, Huckabee AM, Agonias KB, Kazmierczak K, Szczesna-Cordary D, Tanner BCW.
    Am J Physiol Heart Circ Physiol; 2021 Feb 01; 320(2):H881-H890. PubMed ID: 33337957
    [Abstract] [Full Text] [Related]

  • 2. Cardiac contractility, motor function, and cross-bridge kinetics in N47K-RLC mutant mice.
    Wang L, Kazmierczak K, Yuan CC, Yadav S, Kawai M, Szczesna-Cordary D.
    FEBS J; 2017 Jun 01; 284(12):1897-1913. PubMed ID: 28467684
    [Abstract] [Full Text] [Related]

  • 3. Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue.
    Sewanan LR, Shen S, Campbell SG.
    Am J Physiol Heart Circ Physiol; 2021 Mar 01; 320(3):H1112-H1123. PubMed ID: 33449850
    [Abstract] [Full Text] [Related]

  • 4. Hypertrophic cardiomyopathy associated E22K mutation in myosin regulatory light chain decreases calcium-activated tension and stiffness and reduces myofilament Ca2+ sensitivity.
    Zhang J, Wang L, Kazmierczak K, Yun H, Szczesna-Cordary D, Kawai M.
    FEBS J; 2021 Aug 01; 288(15):4596-4613. PubMed ID: 33548158
    [Abstract] [Full Text] [Related]

  • 5. Hypertrophic cardiomyopathy associated Lys104Glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice.
    Huang W, Liang J, Kazmierczak K, Muthu P, Duggal D, Farman GP, Sorensen L, Pozios I, Abraham TP, Moore JR, Borejdo J, Szczesna-Cordary D.
    J Mol Cell Cardiol; 2014 Sep 01; 74():318-29. PubMed ID: 24992035
    [Abstract] [Full Text] [Related]

  • 6. Regulatory light chain phosphorylation augments length-dependent contraction in PTU-treated rats.
    Breithaupt JJ, Pulcastro HC, Awinda PO, DeWitt DC, Tanner BCW.
    J Gen Physiol; 2019 Jan 07; 151(1):66-76. PubMed ID: 30523115
    [Abstract] [Full Text] [Related]

  • 7. Impact of the Myosin Modulator Mavacamten on Force Generation and Cross-Bridge Behavior in a Murine Model of Hypercontractility.
    Mamidi R, Li J, Doh CY, Verma S, Stelzer JE.
    J Am Heart Assoc; 2018 Sep 04; 7(17):e009627. PubMed ID: 30371160
    [Abstract] [Full Text] [Related]

  • 8. Effects of myosin light chain phosphorylation on length-dependent myosin kinetics in skinned rat myocardium.
    Pulcastro HC, Awinda PO, Breithaupt JJ, Tanner BC.
    Arch Biochem Biophys; 2016 Jul 01; 601():56-68. PubMed ID: 26763941
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice.
    Kerrick WG, Kazmierczak K, Xu Y, Wang Y, Szczesna-Cordary D.
    FASEB J; 2009 Mar 01; 23(3):855-65. PubMed ID: 18987303
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prolonged Ca2+ and force transients in myosin RLC transgenic mouse fibers expressing malignant and benign FHC mutations.
    Wang Y, Xu Y, Kerrick WG, Wang Y, Guzman G, Diaz-Perez Z, Szczesna-Cordary D.
    J Mol Biol; 2006 Aug 11; 361(2):286-99. PubMed ID: 16837010
    [Abstract] [Full Text] [Related]

  • 17. Ablation of the N terminus of cardiac essential light chain promotes the super-relaxed state of myosin and counteracts hypercontractility in hypertrophic cardiomyopathy mutant mice.
    Sitbon YH, Kazmierczak K, Liang J, Yadav S, Veerasammy M, Kanashiro-Takeuchi RM, Szczesna-Cordary D.
    FEBS J; 2020 Sep 11; 287(18):3989-4004. PubMed ID: 32034976
    [Abstract] [Full Text] [Related]

  • 18. Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice.
    Yuan CC, Muthu P, Kazmierczak K, Liang J, Huang W, Irving TC, Kanashiro-Takeuchi RM, Hare JM, Szczesna-Cordary D.
    Proc Natl Acad Sci U S A; 2015 Jul 28; 112(30):E4138-46. PubMed ID: 26124132
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.